Navigation Links
MolecularHealth demonstrates Personalized Cancer Therapy Solutions at 2013 CeBIT
Date:3/5/2013

NEW YORK and HEIDELBERG, Germany, March 5, 2013 /PRNewswire/ --  MolecularHealth, a leader in clinico-molecular informatics™, today announced that the company will demonstrate their latest capabilities at CeBIT 2013, taking place in Hannover, Germany March 5-9. The company is advancing precision medicine by providing decision support solutions that translate patient-specific molecular and genomic data, treatment-relevant clinical history, and published scientific evidence in combination with mechanism-based therapy knowledge into safer, more effective drug choices. MolecularHealth's Personalized Cancer Therapy Solutions offer health providers and patients an integrated service that unlocks evidence-based treatment strategies from the genome, patient clinical history and extensive knowledge about drug therapy mechanisms of action.

(Logo: http://photos.prnewswire.com/prnh/20130305/DA68911LOGO)

Benefitting from the unprecedented speed and performance of the SAP HANA® platform, the offering aims to tackle the challenges of immense bodies of disparate medical, biological and drug data, manual and time consuming analysis, and the increasingly complex treatment paradigms affecting pathologists, oncologists and patients and their families. MolecularHealth will demonstrate its Molecular Analysis of Side Effects™ (MASE) and Oncology Decision Support capabilities in the SAP booth, Hall 4 Stand C04. These capabilities reflect SAP's recent entry with the SAP HANA platform and partners such as MolecularHealth into the increasingly accessible field of genomics and next generation sequencing-driven clinical decision support.

About MolecularHealth

MolecularHealth, a clinico-molecular informatics company offering mechanism-based drug safety and Personalized Cancer Therapy Solutions, is advancing precision medicine by translating patient-specific molecular and genomic data, clinical history, drug knowledge and published scientific and medical evidence into safer, more effective drug choices for patients. The company's solutions range from a next generation drug safety assessment and prediction tool that analyzes the molecular basis of adverse events to a treatment decision support offering that informs evidence-based treatment strategies for cancer patients.  MolecularHealth's collaborators include the University of Texas MD Anderson Cancer Center, SAP AG, and the U.S. Food and Drug Administration (FDA). Visit www.molecularhealth.com.

© 2013 The MolecularHealth name and logo are trademarks of Molecular Health AG.

SAP, SAP HANA, and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries.
All other product and service names mentioned are the trademarks of their respective companies.


'/>"/>
SOURCE MolecularHealth
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
4. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
6. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
7. At SIIM 2012 Siemens Healthcare Demonstrates Departmental IT Solutions That Help Administrators Increase Access while Managing Costs
8. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
9. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
10. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
11. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, ... report , "Alzheimer Diagnostic Tests - Medical Devices ... Diagnostic Tests currently in pipeline stage. The ... with comparative analysis of the products at various ... involved in the pipeline product development. It also ...
(Date:2/8/2016)... 2016 CBG Technologies, a U.S. company, ... Recycling Systems, specifically designed for precision parts cleaning. ... and existing vapor degreasers, parts washers and ultrasonic ... continuous recycling and recovers 100% of the solvent ... --> Precision parts manufacturers benefit from this ...
(Date:2/8/2016)... 2016 --> ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible Electroporation, ... Surgery, Ophthalmology, Gynecology) - Global Forecasts to 2020", published ... the forecast period of 2015 to 2020. The market ... CAGR of 10.5% from 2015 to 2020. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... newly redesigned website, federallabs.org . The site houses a wealth of federal ... federal technologies through the process called technology transfer (T2). As a network of ...
(Date:2/8/2016)... ... ... has struggled to quit smoking, a man who has struggled with hair loss – Craig ... problems – and he did. Now Nabat, a serial entrepreneur featured as the October 2015 ... the world and better people's lives. His own experience with nicotine addiction led to the ...
(Date:2/8/2016)... Indianapolis, IN (PRWEB) , ... February 08, 2016 ... ... serving the Indianapolis, IN metro area, has selected the latest beneficiary of their ... nonprofit organization dedicated to preventing bullying in area schools. Donations are now being ...
(Date:2/8/2016)... ... 08, 2016 , ... Eating disorders and post-traumatic stress disorder ... and men with eating disorders report a history of trauma, research suggests that ... an eating disorder. , At the 2016 iaedp Symposium, the workshop, “What ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating ... Moles are derived from a cluster of melanin when exposed to sunlight. Although most ... create a lifetime of embarrassment. Historically, mole removal has involved a painful, ...
Breaking Medicine News(10 mins):